Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth

ABSTRACT

The invention relates to  beta -lapachone derivatives of formula II and compositions containing said compounds:    &lt;IMAGE&gt;  Formula II  wherein, R5, R6 and R7 are as defined in the specification. The compounds are potent inhibitors of neoplastic cell growth and proliferation.

FIELD OF THE INVENTION

This invention is directed to novel o-quinone and o-naphthoquinonederivatives which are structurally related to naturally-occurringlapachones and dunniones. The present invention is also drawn to a novelsynthetic method to produce tricyclic derivatives, including lapachoneand dunnione, as well as the use of these compounds in the inhibition ofneoplastic cell growth.

DESCRIPTION OF THE PRIOR ART

The present invention is drawn toward novel tricyclic naphthoquinonederivatives, a synthetic method for making the derivatives, and use ofthe derivatives to inhibit neoplastic cell proliferation. Thenaphthoquinone derivatives of the present invention are related to thecompounds known by their trivial names as β-lapachone (1)(7,8-dihydro-2,2-dimethyl-2H-naphtho(2,3-b)dihydropyran-7,8-dione) anddunnione (2) (2,3,3-trimethyl-2,3,4,5-tetrahydro-naphtho(2,3-b)dihydrofuran-6,7-dione). ##STR2##

β-lapachone is a naturally occurring product which can be found in smallamounts in the lapacho tree (Tabebuia avellanedae) of South America.β-Lapachone may also be readily synthesized from lapachol (3), anabundant quinone which is also found in the lapacho tree. ##STR3##

In similar fashion, dunnione (2) and its structural isomer α-dunnione(2a)(2,2,3-trimethyl-2,3,4,5-tetrahydro-naphtho(2,3-b)dihydro-furan-6,7-dione)can be isolated from the leaves of Streptocarpus dunnii. ##STR4##

Early work on the synthesis of these related naphthodihydrofurandionesand naphthodihydropyrandiones began with Fieser's 1927 synthesis oflapachol (3) (Fieser, L. F. (1927), J.A.C.S., 49: 857.) The first knownsynthesis of dunniones (2 and 2a) and related naphthoquinones wasperformed by R. G. Cooke and co-workers at the University of Melbourneusing a modification of Fieser's above-noted synthesis. (Cooke, R. G. etal. (1950), Australian J. of Scient. Res., 3:481-94.) In short, theFieser method synthesizes β-lapachol (3) via alkylation of the silversalt of lawsone (i.e., 2-hydroxy-1,4-naphthoquinone) with dimethylallylbromide in absolute ether. This synthetic route yields both theC-alkylated product (lapachol), as well as an O-alkylated by-product.

Cooke et al. modified this general procedure by beginning with thepotassium salt of lawsone rather than the silver salt. The C-alkylatedproduct (lapachol) is separated from the O-alkylated intermediate byacidification, which precipitates the lapachol from solution.

What is left behind is an O-alkylated lawsone derivative, namely,2-(3',3'-dimethylalloxy)-1,4-naphthoquinone (4): ##STR5##

Compound (4) is then subjected to a Claisen rearrangement by refluxingin absolute ethanol to yield2-hydroxy-3-(1',1'-dimethylallyl)-1,4-naphthoquinone (5): ##STR6##

Under these mild conditions, Cooke et al. report that the conversion of(4) to (5) is practically quantitative. However, under more rigorousconditions, mixtures of the 1,2-dimethylallyl and 2,3-dimethylallylisomers are also found.

Treatment of compound (5) with concentrated sulfuric acid yields a2-ethyl-2-methyl derivative of dunnione (6): ##STR7##

In an interesting aside, Professor Cooke appears to have maintained alife-long interest in the dunniones as evidenced by his 1980 paper"Crystal Structure of Dunnione p-Bromophenylhydrazone," which waspublished 30 years after the above-described reference. (Aust. J. Chem.(1980), 33:442-5.)

A group of researchers led by Kenichiro Inoue has published severalarticles discussing the structure and biosynthetic pathways of variousnaphthoquinones isolated from S. dunnii. For instance, in acommunication to the editor, Inoue et al. report the structure ofseveral prenylated naphthoquinones from S. dunnii. In addition todunnione, this reference also describes the isolation andcharacterization of 7-hydroxydunnione, 8-hydroxydunnione, anddehydrodunnione. This reference also describes the 1,4-naphthoquinoneisomer of α-dunnione. This reference is limited solely to isolating theabove-noted compounds from cell cultures of S. dunnii. A full-lengthpaper describing the isolation and characterization of thesenaphthoquinones can be found in a 1983 publication of Inoue et al.(Phytochemistry (1983), 22(3):737-741.)

In a follow-up paper (Phytochemistry (1984), 23(2):313-318) Inoue et al.report a radioisotopic study to determine the biosynthetic pathways ofseveral naphthoquinones and anthroquinones isolated from S. dunnii.Inoue et al. performed this study by inserting ¹³ C- and ² H-labeledprecursors into cell cultures of S. dunnii. The fate of theisotopically-labeled precursors was then tracked. Inoue et al. concludethat all of the dunnione naphthoquinone derivatives are biosynthesizedvia a common 4-(2'-carboxyphenol)-4-oxobutanoic acid precursor. Thisreference describes the formation of the deuterated 2-prenyl ether oflawsone by reacting lawsone with dimethylallyl bromide in the presenceof potassium carbonate. Both deuterated lawsone and the deuterated2-prenyl ether of lawsone were then administered to cell cultures of S.dunnii to determine the intermediacy of lawsone in the synthesis ofdunnione. It must be noted, however, that this reference is silentregarding artificial methods for synthesizing dunnione and dunnionederivatives. Rather, Inoue et al. are limited to a discussion regardingpossible biological pathways for the synthesis of naphthoquinones andanthraquinones in S. dunnii.

A German-language reference to Ruedi and Eugster describes the isolationof partially racemic (-)-dunnione from Calceolaria integrifolia. (Ruediand Eugster (1977), Hel. Chim. Acta, 60(3) 96: 945-947.) According tothe authors, this appears to be the first record of the occurrence ofdunnione outside the family Gesneriaceae. In Gesneriaceae, dunnione isusually found as the dextrorotary enantiomer.

While dunniones, lapachones, and several derivatives thereof have beendescribed in the prior art, no biological utility has been described inany of the above references, nor has any direct utility been describedfor any of the above-noted naphthofurandione or naphthopyrandionederivatives.

In the patent literature, Adams et al., U.S. Pat. No. 4,778,805,describe 4,7-benzofurandione derivatives which are useful as inhibitorsof leukotriene synthesis. Because the benzofurandiones described byAdams et al. tend to inhibit mammalian leukotriene biosynthesis, theyare described as useful therapeutic agents for treating allergicconditions, asthma, psoriasis, and other maladies which are biologicallymediated by various leukotrienes.

Petraitis et al., U.S. Pat. No. 5,244,917, describe a large number ofsubstituted naphthofurans which find use as anti-inflammatory agents.

None of the above references, taken alone or in any combination, areseen as describing the presently disclosed invention.

SUMMARY OF THE INVENTION

One aspect of the present invention is directed to a novel method tosynthesize tricyclic o-naphthoquinones. The method is directed tosynthesizing compounds of Formula I or II: ##STR8## wherein R¹ -R⁶ areeach, independently, selected from the group consisting of H, C₁ -C₆alkyl, C₁ -C₆ alkenyl, C₁ -C₆ alkoxy, C₁ -C₆ alkoxycarbonyl, --(CH₂)_(n)-aryl, --(CH₂)_(n) -heteroaryl, --(CH₂)_(n) -heterocycle, and--(CH₂)_(n) -phenyl; or R₁ and R² combined are a single substituentselected from the above group, and R³ and R⁴ combined are a singlesubstituent selected from the above group, in which case--is a doublebond; and R⁷ is H, OH, C_(1-C) ₆ alkyl, C_(1-C) ₆ alkenyl, C_(1-C) ₆alkoxy, C₁ -C₆ alkoxycarbonyl, --(CH₂)_(n) -amino, --(CH₂)_(n) -aryl,--(CH₂)_(n) -heteroaryl, --(CH₂)_(n) -heterocycle, or --(CH₂) _(n)-phenyl, wherein n is an integer of from 0 to 10.

The method includes the steps of alkylating a Group IA metal salt oflawsone with an allyl halide of the formula: ##STR9## in the presence ofM-I; wherein R⁸ and R⁹ are each, independently, selected from the groupconsisting of H, C₁ -C₆ alkyl, C₁ -C₆ alkenyl, C₁ -C₆ alkoxy, C₁ -C₆alkoxycarbonyl, --(CH₂)_(n) --aryl, --(CH₂)_(n) -heteroaryl, --(CH₂)_(n)-phenyl; and X is a halide, and M is a Group IA metal; which yields amixture of C-alkylated and O-alkylated lawsone derivatives.

The mixture of C-alkylated and O-alkylated lawsone derivatives is thencyclized to yield a tricyclic ortho-naphthoquinone.

The present invention is further drawn to a method of synthesizingcompounds of Formula I or II: ##STR10## wherein R¹ -R⁶ are each,independently, selected from the group consisting of H, C₁ -C₆ alkyl, C₁-C₆ alkenyl, C₁ -C₆ alkoxy, C₁ -C₆ alkoxycarbonyl, --(CH₂)_(n) -aryl,--(CH₂)_(n) -heteroaryl, --(CH₂)_(n) -heterocycle, and --(CH₂)_(n)-phenyl; or R¹ and R² combined are a single substituent selected fromthe above group, and R³ and R⁴ combined are a single substituentselected from the above group, in which case--is a double bond; and R⁷is H, OH, C₁ -C₆ alkyl, C₁ -C₆ alkenyl, C₁ -C₆ alkoxy, C₁ -C₆alkoxycarbonyl, --(CH₂)_(n) -amino, --(CH₂)_(n) -aryl, --(CH₂)_(n)-heteroaryl, --(CH₂)_(n) -heterocycle, or --(CH₂)_(n) -phenyl; and n isan integer of from 0 to 10.

The synthetic method includes the steps of synthesizing a lithium saltof lawsone by contacting lawsone at a temperature equal to or less thanabout -78° C. with lithium hydride. Whereby the lithium salt isafforded.

The lithium salt of lawsone is then alkylated with an allyl halide ofthe formula: ##STR11## in the presence of M-I, wherein R⁸ and R⁹ areeach, independently, selected from the group consisting of H, C₁ -C₆alkyl, C₁ -C₆ alkenyl, C₁ -C₆ alkoxy, C₁ -C₆ alkoxycarbonyl, --(CH₂)_(n) -aryl, --(CH₂)_(n) -heteroaryl, --(CH₂)_(n) -heterocycle, and--(CH₂)_(n) -phenyl; X is a halide, and M is a Group IA metal, whichyields a mixture of C-alkylated and O-alkylated lawsone derivatives.

The mixture of C-alkylated and O-alkylated lawsone derivatives is thenseparated from one another to yield a first portion of C-alkylatedderivatives and a portion of O-alkylated derivatives. The portion ofO-alkylated lawsone derivatives is then rearranged to yield a secondportion of C-alkylated lawsone derivatives. The first and secondportions of C-alkylated lawsone derivatives are cyclized to yield atricyclic ortho-naphthoquinone.

Using the synthetic method described above, several novel compounds havebeen synthesized. Among these compounds are compounds selected from thegroup consisting of Formula I or II: ##STR12## wherein R¹ -R⁶ are each,independently, selected from the group consisting of H, C₁ -C₆ alkyl, C₁-C₆ alkenyl, C₁ -C₆ alkoxy, C₁ -C₆ alkoxycarbonyl, --(CH₂) _(n) -aryl,--(CH₂)_(n) -heteroaryl, --(CH₂) _(n) -heterocycle, and --(CH₂)_(n)-phenyl; or R¹ and R² combined are a single substituent selected fromthe above group, and R³ and R⁴ combined are a single substituentselected from the above group, in which case--is a double bond: and R⁷is H, OH, C₁ -C₆ alkyl, C₁ -C₆ alkenyl, C₁ -C₆ alkoxy, C₁ -C₆alkoxycarbonyl, --(CH₂)_(n) -amino, --(CH₂) _(n) -aryl, --(CH₂)_(n)-heteroaryl, --(CH₂)_(n) -heterocycle, or --(CH₂)_(n) -phenyl, and n isan integer of from 0 to 10, and salts thereof; except when R¹, R², R³,R⁵ and R⁶ are methyl, then R⁴ and R⁷ are substituents other thanhydrogen; and when R², R³ and R⁴ are methyl, then R¹ is a substituentother than hydrogen.

A distinct advantage of the present synthetic method is that it allowsfor the synthesis of novel o-naphthoquinone derivatives, includinglapachone and dunnione derivatives, using lawsone as a startingmaterial. Lawsone is a commodity chemical which can be readily purchasedin large quantities. This is a vast improvement over isolation of theseproducts from natural sources or synthesis from naturally-occurringprecursors.

The presently described synthetic method is also remarkably efficientand clean. The overall synthesis yields dunnione, lapachone, and othertricyclic o-naphthoquinone derivatives in heretofore unattainable yieldsand purity.

The synthesis is also quite easy, thereby avoiding the cumbersomemanipulations required in prior art synthetic methods.

Of equal importance, the biological activity of the compounds describedherein is remarkable in that the compounds are potent inhibitors ofneoplastic cell growth and proliferation. The compounds described hereinfind use as chemotherapeutic agents in the treatment of a wide range ofneoplasms, including cancers of the prostate, breast, colon, and lung.The compounds exhibit their anti-proliferative effects in heretoforeunknown, minute concentrations.

In light of the newly-discovered biological activity of these compounds,another aspect of the present invention is drawn to a method ofinhibiting growth of cancer cells by contacting the cells with one ormore compounds described herein. More specifically, this aspect of thepresent invention is drawn to a method of inhibiting growth of a cancercell which comprises contacting the cancer cell with an effectivegrowth-inhibiting amount of a compound selected from the groupconsisting of 4-(C₁ -C₆ alkoxy)-1,2-naphthoquinones, 4-(C₁ -C₆alkenyloxy)-1,2-naphthoquinones, 4-(C₁ -C₆carbonyloxy)-1,2-naphthoquinones, 4-(C₁ -C₆aryloxy)-1,2-naphthoquinones, 4-(C₁ -C₆heteroaryloxy)-1,2-naphthoquinones, 4-(benzyloxy)-1,2-naphthoquinone,4-(C₃ -C₆ cycloaryloxy)-1,2-naphthoquinones, 4-(C₃ -C₆heterocycloaryloxy)-1,2-naphthoquinones, a compound of Formula I or II:##STR13## wherein R¹ -R⁶ are each, independently, selected from thegroup consisting of H, C₁ -C₆ alkyl, C₁ -C₆ alkenyl, C₁ -C₆ alkoxy, C₁-C₆ alkoxycarbonyl, --(CH₂)_(n) -aryl, --(CH₂)_(n) -heteroaryl,--(CH₂)_(n) -heterocycle, and --(CH₂)_(n) -phenyl; or R¹ and R² combinedare a single substituent selected from the above group, and R³ and R⁴combined are a single substituent selected from the above group, inwhich case--is a double bond; R⁷ is H, OH, C₁ -C₆ alkyl, C₁ -C₆ alkenyl,C₁ -C₆ alkoxy, C₁ -C₆ alkoxycarbonyl, --(CH₂)_(n) -amino, --(CH₂) _(n)-aryl, --(CH₂)_(n) -heteroaryl, --(CH₂)_(n) -heterocycle or --(CH₂)_(n)-phenyl, and wherein n is an integer of from 0 to 10;pharmaceutically-suitable salts thereof, and combinations thereof.

The method includes administering to a human cancer patient in needthereof an amount of one or more of the above-described compounds whichis effective to inhibit the growth of the cancer cell.

The present method for the inhibition of neoplastic cell growth has bothin vivo and in vitro applications. In vivo, the method encompasses thetherapeutic treatment of neoplastic growths in mammals, includinghumans. The treatment includes administering an effective cancer cellgrowth-inhibiting amount of a compound as described above to a person oranimal in need thereof. In vitro, the method for neoplastic cell growthinhibition is effective for inhibiting the proliferation of a largenumber of different human cancer cell lines, including breast cancer,lung cancer, colon cancer, and prostate cancer.

The present invention is also drawn to a pharmaceutical unit dosage formwhich comprises an amount of a compound selected from the groupconsisting of 4-(C₁ -C₆ alkoxy)-1,2-naphthoquinones, 4-(C₁ -C₆alkenyloxy)-1,2-naphthoquinones, 4-(C₁ -C₆carbonyloxy)-1,2-naphthoquinones, 4-(C₁ -C₆aryloxy)-1,2-naphthoquinones, 4-(C₁ -C₆heteroaryloxy)-1,2-naphthoquinones, 4-(benzyloxy)-1,2-naphthoquinone,4-(C₃ -C₆ cycloaryloxy)-1,2-naphthoquinones, 4-(C₃ -C₆heterocycloaryloxy)-1,2-naphthoquinones, a compound of Formula I or II:##STR14## wherein R¹ -R⁶ are each, independently, selected from thegroup consisting of H, C₁ -C₆ alkyl, C₁ -C₆ alkenyl, C₁ -C₆ alkoxy, C₁-C₆ alkoxycarbonyl, --(CH₂)_(n) -aryl, --(CH₂)_(n) -heteroaryl,--(CH₂)_(n) -heterocycle, and --(CH₂)_(n) -phenyl; or R¹ and R² combinedare a single substituent selected from the above group, and R³ and R⁴combined are a single substituent selected from the above group, inwhich case--is a double bond; R⁷ is H, OH, C₁ -C₆ alkyl, C₁ -C₆ alkenyl,C₁ -C₆ alkoxy, C₁ -C₆ alkoxycarbonyl, --(CH₂)_(n) -amino, --(CH₂)_(n)-aryl, --(CH₂)_(n) -heteroaryl, --(CH₂)_(n) -heterocycle, or --(CH₂)_(n)-phenyl, and wherein n is an integer of from 0 to 10;pharmaceutically-suitable salts thereof, and combinations thereof;wherein the amount is effective to inhibit growth of cancer cells in ahuman cancer patient following administration thereto.

In light of the above discussion, a principal aim of the presentinvention is to provide novel compounds and pharmaceutical compositionswhich inhibit the growth of cancer cells both in vitro and in vivo atvery low dosages.

It is further an aim of the present invention to provide novel syntheticmethods for making the compounds described herein. Specifically, it isan aim of the present invention to provide a novel synthetic methodologyfor the manufacture of o-naphthoquinone derivatives, including tricyclico-naphthofurandione and o-naphthopyrandione derivatives.

Another aim of the present invention is to provide novel pharmaceuticalunit dosage forms containing naphthoquinone derivatives which inhibitthe growth of cancer cells when administered to mammals in need thereof,including human cancer patients in need thereof.

Further aims, objects, and advantages of the presently describedsynthetic methods and products will become clear upon a complete readingof the following Detailed Description, drawings, and attached claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a semi-log graph depicting the fraction of cell survival inthe presence of β-lapachone and 3-hydroxy-β-lapachone of colon cancercells HT29.

FIG. 2 is a semi-log graph depicting the fraction of cell survival inthe presence of β-lapachone and 3-hydroxy-β-lapachone of colon cancercells BE.

FIG. 3 is a semi-log graph depicting the fraction of cell survival inthe presence of β-lapachone and 3-hydroxy-β-lapachone of lung cancercells A549.

FIG. 4 is a semi-log graph depicting the fraction of cell survival ofA549 lung cancer cells in the presence of β-lapachone and2-methyl-2,3,4,5-tetrahydro-naphtho(2,3-b) dihydrofuran-6,7-dione (alsocalled 3,3-DINOR-dunnione), designated in the graph as "Drug A."

FIG. 5 is a semi-log graph depicting the fraction of cell survival ofA549 lung cancer cells in the presence of Drug C (dunnione, i.e.,2,3,3-trimethyl-2,3,4,5-dihydro-naphtho (2,3-b)dihydrofuran-6,7-dione)and Drug B (2,3-dimethyl-2,3,4,5-dihydro-naphtho(2,3-b)dihydrofuran-6,7-dione, also called 3-NOR-dunnione).

FIG. 6 is a semi-log graph depicting the fraction of cell survival ofbreast cancer cells MCF7 in the presence of β-lapachone and3-hydroxy-β-lapachone.

FIG. 7 is a semi-log graph depicting the fraction of cell survival ofbreast cancer cells MCF7 in the presence of β-lapachone and Drug A(2-methyl-2,3,4,5-tetrahydro-naphtho (2,3-b)dihydrofuran-6,7-dione, alsocalled 3,3-DINOR-dunnione).

FIG. 8 is a semi-log graph depicting the fraction of cell survival ofbreast cancer cells MCF7 in the presence of Drug C (dunnione) and Drug B(2,3-dimethyl-2,3,4,5-dihydro-naphtho(2,3-b)dihydrofuran-6,7-dione, alsocalled 3-NOR-dunnione).

FIGS. 9A and 9B combined depict an electrophoresis plate runillustrating the ability of several of the compounds described herein toinduce Topoisomerase II-mediated cleavage of DNA. The far left-hand laneof FIG. 9A is a lane containing DNA alone and the adjacent lane containsDNA and Topo II. The groups of lanes labeled 1-9 in FIGS. 9A and 9Bdepict varying concentrations of different compounds described herein incombination with DNA and Topo II.

DETAILED DESCRIPTION OF THE INVENTION

The compounds described herein may be prepared using the reactions,techniques, and general synthetic procedures described herein below.Each of the references cited below are hereby incorporated herein byreference. The various reactions may be performed in various solventswhich are appropriate to the reagents and materials employed and whichare suitable for the transformation being effected. It is understood bythose skilled in the art of organic synthesis that the functionalitypresent on portions of a given molecule must be compatible with thereagents and reaction conditions proposed.

The synthetic method described herein generally and preferably useslawsone (2-hydroxy-1,4-naphthoquinone) as a starting reagent. Lawsone isa commodity chemical which can be purchased in kilogram quantities fromseveral commercial suppliers. (For instance, the Aldrich Chemical Co.,Inc., Milwaukee, Wis.)

One aspect of the present invention is drawn to a preparative-scalealkylation of a Group IA metal salt of lawsone(2-hydroxy-1,4-naphthoquinone) with allyl halides to yield tricyclicortho-naphthoquinones. As described in full, below, the resultanttricyclic o-naphthoquinones are potent inhibitors of neoplastic cellproliferation and growth. Consequently, the compounds described hereinare useful in the therapeutic treatment of cancerous tumors and otherneoplasms.

Preparative Alkylation of Lawsone

Alkylation of a Group IA metal salt of lawsone (i.e., lithium lawsone,sodium lawsone, potassium lawsone, etc.) with an allyl halide yields amixture of C-alkylated products and O-alkylated products. The presentsynthetic method utilizes these two intermediate products to synthesizetricyclic o-naphthoquinone products such as β-lapachone, dunnione,α-dunnione, and related derivatives. The present inventors havediscovered that these compounds are potent inhibitors of neoplastic cellgrowth and proliferation.

Reaction I illustrates the initial synthesis of the lawsone salt,followed by reaction with an allyl halide. For clarity and brevity, theremainder of the Detailed Description shall refer to the preferredembodiment of the synthesis, wherein the lawsone salt is a lithium saltand the allyl halide is an allyl bromide. This is for sake of clarityonly. The presently described synthetic method functions with equalsuccess using other Group IA metal salts of lawsone and other allylhalides, such as allyl chlorides. ##STR15##

With reference to Reaction I, preferably, a lithium salt of lawsone isprepared by dissolving lawsone (10) in a suitable solvent, preferablydimethylsulfoxide (DMSO), and then adding lithium hydride, LiH. A noveland preferred protocol is to cool the lawsone solution to -78° C. priorto the addition of the LiH, and then add the LiH to the solidifiedreaction mixture. The solution is then slowly warmed to roomtemperature. As the solution warms, the LiH is slowly dissolved into thereaction mixture allowing for easy control of the evolution of hydrogen.The controlled evolution of hydrogen also eliminates the need to purgeoxygen from the reaction solution by bubbling with a non-reactive gas.This makes generation of the lithium salt and the subsequent alkylationless cumbersome than prior art methods.

Alkylation proceeds by the addition of an allyl halide, preferably anallyl bromide (12) and a Group IA metal iodide, M-I, wherein M is aGroup IA metal (preferably lithium), to the reaction mixture. Additionof the metal iodide serves to transform the allyl bromide in situ intoan allyl iodide, which then reacts with the lawsone salt.

This in situ generation of an allyl iodide is another novel feature ofthe present invention. Allyl iodides are much more reactive than allylbromides or allyl chlorides and are therefore desirable for use inalkylations. However, allyl iodides are also unstable and have a shortshelf-life. Therefore, rather than working directly with the unstableallyl iodide, the allyl iodide is generated in situ, where it reactswith the lawsone salt. In addition, the high reactivity of the allyliodide so formed increases the overall yield of the synthesis.

As shown Reaction I, R and R' are, independently, H, C₁ -C₆ alkyl, C₁-C₆ alkenyl, C₁ -C₆ alkoxy, C₁ -C₆ alkoxycarbonyl, --(CH₂)_(n) -aryl,--(CH₂)_(n) -heteroaryl, --(CH₂)_(n) -heterocycle, or --(CH₂)_(n)-phenyl, or R¹ and R² combined are H, and R³ and R⁴ combined are H, inwhich case--is a double bond: and R⁷ is H, C₁ -C₆ alkyl, C₁ -C₆ alkenyl,C₁ -C₆ alkoxy, C₁ -C₆ alkoxycarbonyl, --(CH₂)_(n) -aryl, --(CH₂)_(n)-heteroaryl, --(CH₂)_(n) -heterocycle, or --(CH₂)_(n) -phenyl, wherein nis an integer of from 0 to 10.

Reaction I yields a mixture of C-alkylated lawsone derivatives (13),O-alkylated derivatives (14), and unreacted lawsone (10).

The O-alkylated derivatives (14) precipitate from solution and can beseparated by filtration, centrifugation, or any other suitable means forseparating solids from a reaction solution. The unreacted lawsone andthe C-alkylated derivatives (13) may then be isolated based upondifferences in their respective acidities by any number of well knownmeans.

Illustratively, the reaction mixture containing lawsone and C-alkylatedderivatives (13) is acidified and extracted into ethyl acetate. Thelawsone is then re-extracted into a sodium bicarbonate solution (˜5%)and recovered by acidification. The less basic C-alkylated derivativesare recovered from the organic solvent by extraction with sodiumhydroxide (˜2N) and recovered by acidification.

Overall yield is approximately 40% for the C-alkyl derivatives andapproximately 30% for the O-alkyl derivatives. ##STR16##

As shown in Reaction II, the C-alkylated naphthoquinone derivatives (13)can be converted into tricyclic o-naphthoquinone products viacyclization by treatment with concentrated sulfuric acid using wellestablished procedures. (See, for instance, S. C. Hooker (1892), J.Chem. Soc., 61:611.) When R and/or R' are substituents other thanhydrogen, the six-membered dihydro-naphthopyrandione derivatives (15)are formed. Presumably, this arises due to stabilization of thecarbocation of the secondary or tertiary carbon center. If R and R' areboth hydrogen, five-membered dihydro-naphthodihydrofurandiones (16) areobtained.

Reaction III shows a Claisen rearrangement of the O-alkylatedderivatives (14) to yield a rearranged intermediate (17). As depicted,the rearrangement is accomplished by refluxing in toluene (although anysuitable solvent will suffice). The Claisen rearrangement is well knownto synthetic organic chemists. See, for instance, R. G. Cooke,Australian J. Sci. Res., above. In the same fashion as Reaction II, therearranged product (17) of Reaction III may be cyclized by treatmentwith concentrated sulfuric acid. ##STR17##

Additional derivatives of the above-described tricyclic o-naphthoquinonecompounds can also be synthesized by modifying the synthetic pathwayused to cyclize the third fused ring. An illustrative example, depictingthe synthesis of 3-hydroxy-β-lapachone (19) is shown in Reaction IV,below: ##STR18## Here, an allyl derivative of lawsone, depicted inReaction IV as lapachol (13) (wherein R and R' are methyl), is treatedwith m-chloroperoxybenzoic acid to afford the epoxide (18). Preferably,the epoxide is not isolated. Rather, the epoxide is directly transformedinto the tricyclic o-naphthoquinone derivative (19) by treatment withboron trifluoride. The overall yield of product (19) is approximately50%.

The reaction illustrated in Reaction IV is a distinct improvement overprior art ring-closure transformations leading from (13) to (19) becauseit is far less cumbersome. The intermediate need not be isolated and theyield is quite high.

Still other tricyclic o-naphthoquinone derivatives can be synthesizedvia the reaction depicted in Reaction V. Here, a fully aromaticderivative. 3,3-DINOR-2,3-dehydrodunnione, is synthesized. ##STR19##Here, lawsone is reacted with an aldehyde, such as propionaldehyde toyield a vinyl-p-quinone (20). The aldehyde may be selected from a widerange of suitable aldehydes and may contain additional functionalities.Suitable aldehydes include C₁ -C₆ linear or branched aliphaticaldehydes, as well as C₁ -C₆ dicarbonyl, cyclic, heterocyclic, aromatic,and heteroaromatic aldehydes. Cyclization of (20) under acid catalysisand mild oxidation yields the fully-aromatic dunnione derivative (21).Illustratively, the ring closure in Reaction V can be accomplished bytreatment of (20) with mercuric acetate (Hg(CH₃ CO₂)₂, a mild oxidant)in the presence of acetic acid.

The 3-hydroxy-naphtho(2,3-b)dihydropyran-7,8-dione derivatives (19)(wherein R" is hydrogen), shown in Reaction IV, can be furtherderivatized to hydrophobic, cationic, and anionic ortho-naphthoquinonesby reaction with mono-acids, amino acids, or di-acids, as shown inReactions VI, VII, and VIII, respectively. ##STR20##

Reaction VI depicts the synthesis of mono-acid derivatives, such as the3-O-acetyl derivative (22c). Reaction VII illustrates the synthesis ofamino acid ester derivatives, such as the 3-O-alanyl derivative (23).Reaction VIII shows the synthesis of di-acid derivatives, such as the3-O-malonyl derivative (24).

The preferred method to accomplish the transformation shown in ReactionVI is to react the 3-hydroxy-β-lapachone with an acid, R¹⁰ COOH, and thecorresponding carbonyldiimidazole, CDI, in the presence of anon-nucleophilic base. As illustrated here, DBU (i.e.,1,8-diazabicyclo(5.4.0)undec-7-ene) is used. DBU is preferred. However,several equivalent reagents are known to those skilled in the art.Reaction VI can be used to generate, inter alia, carbonyl anddi-carbonyl derivatives.

Reaction VII illustrates the conversion of a monoacid formed in ReactionVI into an amino acid derivative. As shown, the conversion to an aminoacid salt is accomplished by treatment with HBr in a suitable solvent(e.g., diethyl ether).

Reaction VIII illustrates the synthesis of a di-acid derivative bytreating a t-butyl ester generated in Reaction VI with a strong acid.

Examples and a further description of Reaction VI, VII, and VIII areincluded in the Examples section, below.

Biological Activity of the Tricyclic o-Naphthoquinones

Of great significance in the present invention is the utility of thedescribed naphthoquinones to inhibit the growth and proliferation ofneoplastic cells. Further still, in standard in vitro testing, thenaphthoquinones described herein induce cell death in several neoplasticcell lines at drug concentrations smaller than 10 μM. The tricyclicnaphthoquinones of the present invention have been shown to cause celldeath in accepted in vitro test cultures for human breast cancer, lungcancer, colon cancer, and prostate cancer at minute concentrationsheretofore undescribed in the scientific literature.

FIGS. 1-8 illustrate a series of experiments designed to illustrate theability of the subject o-naphthoquinones to induce cell death instandard neoplastic cell lines. Each graph has as its X-axis theconcentration of the particular compound being tested. The Y-axis ofeach graph is a semi-logarithmic scale of at least 4 orders of magnituderepresenting the fraction of cell survival in each of the culturestested. A standardized protocol was used throughout all of the testcultures. The test protocol and neoplastic cell lines tested, as well asa complete description of each of the graphs shown in FIGS. 1-8 follows:

Cell Culture and Drug Testing Protocol

For each of the in vitro tests whose results are depicted in FIGS. 1-8,the following protocol was followed.

Day 1:

10 standard culture flasks for each drug to be tested are plated with5×10⁵ cells in 5 mL of media and allowed to incubate for 16-24 hours at37° C.

Day 2:

Fresh stocks of the compounds to be evaluated are prepared in sterileDMSO. For each drug, two of the ten culture flasks prepared on Day 1 areused as controls. The control flasks are treated with DMSO only. Fourflasks for each compound are then treated with serially-dilutedconcentrations of the compound (1, 5, 10, 50 μm or 2, 10, 20, 100 μm).The remaining flasks are left untouched. The cells are incubated for 4hours at 37° C.

After 4 hours the control flasks are counted (2 counts for each flask)and the cells per mL calculated based on the average of the controlcounts. The cells are then replated into six 60 mm dishes for each flaskfrom dilutions based on the cells/mL of the control. (In the varioustest runs, cell concentrations ranged from approximately 50 toapproximately 800 cells per mL.) Day 15-20:

The cells are monitored for colony formation. When visible, the cellsare stained with 0.5% crystal violet (in 95% EtOH) and counted. Theplating efficiency for each dish is then calculated. The platingefficiencies of the six dishes for each flask are averaged and thestandard deviation is calculated. The fraction of cell survival at eachconcentration is determined based on the controls and plotted as logfraction of cell survival±standard deviation versus the dose of thecompound.

The ED₅₀ results of the testing, and the respective figures whichgraphically illustrate the test results are summarized as follows:

    ______________________________________                                        Colony Experiments                                                            Cell Line   ED.sub.50 Values                                                  ______________________________________                                        HT29        ED.sub.50 (Lap) = 4.8 μM                                                                   FIG. 1                                                        ED.sub.50 (OH-Lap) = 15.4 μM                                   BE          ED.sub.50 (Lap) = 8 μM                                                                     FIG. 2                                                        ED.sub.50 (OH-Lap) = 0.6 μM                                    A549        ED.sub.50 (Lap) = 6.1 μM                                                                   FIG. 3                                                        ED.sub.50 (OH-Lap) = 18 μM                                     A549        ED.sub.50 (Lap) = 5.8 μM                                                                   FIG. 4                                                        ED.sub.50 (Drug A) = 6 μM                                      A549        ED.sub.50 (Drug B) = 5.6 μM                                                                FIG. 5                                                        ED.sub.50 (Drug C) = 4.3 μM                                    MCF7        ED.sub.50 (Lap) = 9.8 μM                                                                   FIG. 6                                                        ED.sub.50 (OH-Lap) = 7.7 μM                                    MCF7        ED.sub.50 (Lap) = 1.6 μM                                                                   FIG. 7                                                        ED.sub.50 (Drug A) = 1.6 μM                                    MCF7        ED.sub.50 (Drug B) = 1.4 μM                                                                FIG. 8                                                        ED.sub.50 (Drug C) = 1.4 μM                                    ______________________________________                                    

Effectiveness against colon cancer:

The cell lines HT29 and BE are both human colon cancer cell lines whichare used to test the effectiveness of a given agent against cancer cellgrowth and proliferation. FIGS. 1 and 2 depict the cell survival incultures of HT29 and BE upon the addition of β-lapachone () and3-hydroxy-β-lapachone (◯). The HT29 and BE cell cultures were preparedand tested according to the protocol given above.

As clearly shown in FIGS. 1 and 2, at a concentration of approximately10 μM, β-lapachone already significantly impacts upon the ability of theHT29 and BE cells to reproduce. 3-Hydroxy-β-lapachone also significantlylimits the reproductive ability of these cancer cell lines.

In FIG. 1, the ED₅₀ value for β-lapachone is 4.8 μM, and the ED₅₀ for3-hydroxy-β-lapachone is 15.4 μM. (Bear in mind that the Y-axes in FIGS.1-8 are logarithmic, not linear.)

For the BE cell line tested, the ED₅₀ for the β-lapachone plot shown inFIG. 2 is 8 μM, while the ED₅₀ for 3-hydroxy-β-lapachone is 0.6 μM.

The numerical values and standard deviations of the individual datapoints presented in FIGS. 1 and 2 are tabulated in Tables 1 and 2,respectively.

                  TABLE 1                                                         ______________________________________                                        Fraction of Cell Survival                                                     HT29 With β-Lapachone and 3-Hydroxy-β-lapachone (FIG. 1)            Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          0.9868          0.0935                                             1          0.9669          0.1228                                             5          0.4901          0.0480                                             10         0.0000          0.0000                                             50         0.0000          0.0000                                             0          1.0132          0.0688                                             2          1.5232          0.1125                                             10         1.1854          0.0532                                             20         0.0232          0.0020                                             100        0.0000          0.0000                                             ______________________________________                                    

                  TABLE 2                                                         ______________________________________                                        Fraction of Cell Survival                                                     BE With β-Lapachone and 3-Hydroxy-β-lapachone (FIG. 2)              Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          1.1111          0.0731                                             2          0.0117          0.0082                                             10         0.1579          0.0126                                             20         0.0439          0.0102                                             100        0.0000          0.0000                                             0          0.8889          0.0850                                             2          0.9293          0.1280                                             10         0.3918          0.0627                                             20         0.0102          0.0046                                             100        0.0000          0.0000                                             ______________________________________                                    

Effectiveness against lung cancer:

FIGS. 3, 4, and 5 depict the results of studies of the effectiveness ofseveral different tricyclic o-naphthoquinones against lung cancer cellsA549. The compounds tested were β-lapachone, 3-hydroxy-β-lapachone,3,3-DINOR-dunnione (designated "Drug A" in the figures), 3-NOR-dunnione(designated "Drug B" in the figures) and dunnione itself (designated"Drug C" in the figures). A legend for the figures is provided below.The cell lines were cultured and the compounds evaluated according tothe standard protocol described above.

    ______________________________________                                        FIGURE LEGEND                                                                 Designation                                                                           Formula            Trivial Name                                       ______________________________________                                        Drug A                                                                                 ##STR21##         3,3-DINOR-dunnione                                 Drug B                                                                                 ##STR22##         3-NOR-dunnione                                     Drug C                                                                                 ##STR23##         dunnione                                           Drug D                                                                                 ##STR24##         3,3-DINOR-2,3- dehydrodunnione                     ______________________________________                                    

All of the compounds tested exhibited excellent ED₅₀ values against theproliferation of A549 lung cancer cells. For instance, in FIG. 3, theED₅₀ for β-lapachone () is 6.1 μM, and the ED₅₀ for3-hydroxy-β-lapachone (◯) is 18 μM. The data in FIG. 4 indicate thatED₅₀ (β-lapachone) ()=5.8 μM, and ED₅₀ (3,3-DINOR-dunnione) (◯)=6 μM.ED₅₀ (3-NOR-dunnione) ()=5.6 μM in FIG. 5, and the ED₅₀ for dunnione(◯) itself is a remarkably low 4.3 μM.

The numerical values and standard deviations of the individual datapoints presented in FIGS. 3, 4, and 5 are tabulated in Tables 3-8,below:

                  TABLE 3                                                         ______________________________________                                        Fraction of Cell Survival                                                     A549 With β-Lapachone (FIG. 3)                                           Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          1.5556          0.0327                                             1          2.6528          0.0667                                             5          1.5833          0.0899                                             10         0.0000          0.0000                                             50         0.1771          0.1017                                             ______________________________________                                    

                  TABLE 4                                                         ______________________________________                                        Fraction of Cell Survival                                                     A549 With 3-Hydroxy-β-lapachone (FIG. 3)                                 Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          0.4444          0.0197                                             1          3.0417          0.0978                                             5          2.3924          0.0637                                             10         1.5330          0.0431                                             50         0.0000          0.0000                                             ______________________________________                                    

                  TABLE 5                                                         ______________________________________                                        Fraction of Cell Survival                                                     A549 With β-Lapachone (FIG. 4)                                           Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          1.0161          0.0818                                             1          0.8552          0.0580                                             5          0.8966          0.0303                                             10         0.0069          0.0027                                             50         0.0000          0.0000                                             ______________________________________                                    

                  TABLE 6                                                         ______________________________________                                        Fraction of Cell Survival                                                     A549 With "Drug A" (3,3-DINOR-Dunnione) (FIG. 4)                              Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          0.9840          0.0585                                             1          1.1080          0.0705                                             5          1.2115          0.0238                                             10         0.0172          0.0044                                             50         0.0023          0.0006                                             ______________________________________                                    

                  TABLE 7                                                         ______________________________________                                        Fraction of Cell Survival                                                     A549 With "Drug B" (3-NOR-Dunnione) (FIG. 5)                                  Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          1.0962          0.0724                                             1          0.8972          0.1169                                             5          0.8190          0.0950                                             10         0.0024          0.0031                                             50         0.0000          0.0000                                             ______________________________________                                    

                  TABLE 8                                                         ______________________________________                                        Fraction of Cell Survival                                                     A549 With "Drug C" (Dunnione) (FIG. 5)                                        Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          0.9088        0.1003                                               1          1.0962        0.0888                                               5          0.3997        0.0284                                               10         0.0000        0.0000                                               50         0.0000        0.0000                                               ______________________________________                                    

Effectiveness against breast cancer:

In the same fashion as the above tests, several lapachone and dunnionederivatives were evaluated for their efficacy in inhibiting theproliferation of breast cancer cells. In this instance, the cancer cellline utilized was MCF7.

FIG. 6 depicts the fraction of cell survival for a series of MCF7 cellcultures exposed to β-lapachone () and 3-hydroxy-β-lapachone (◯). Here,the ED₅₀ for β-lapachone was found to be 9.8 μM, while the ED₅₀ for3-hydroxy-β-lapachone was found to be 7.7 μM.

FIG. 7 depicts a comparative cell survival study between β-lapachone ()and 3,3-DINOR-dunnione ("Drug A") (◯). In this study, the ED₅₀ for bothβ-lapachone and 3,3-DINOR-dunnione was found to be a very low 1.6 μM.

FIG. 8 depicts an identical comparative cell survival study between3-NOR-dunnione ("Drug B") () and dunnione itself ("Drug C") (◯). TheED₅₀ levels in this study were also shown to be remarkably low. For boththe 3-NOR-dunnione and dunnione itself, the ED₅₀ was found to be 1.4 μM.

The numerical values and standard deviations of the individual datapoints presented in FIGS. 6, 7, and 8 are tabulated in Tables 9-14,below.

                  TABLE 9                                                         ______________________________________                                        Fraction of Cell Survival                                                     MCF7 With β-Lapachone (FIG. 6)                                           Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          0.5770          0.0152                                             1          1.5             0.2665                                             5          0.0000          0.0000                                             10         0.0000          0.0000                                             50         0.0032          0.0010                                             ______________________________________                                    

                  TABLE 10                                                        ______________________________________                                        Fraction of Cell Survival                                                     MCF7 With 3-Hydroxy-β-lapachone (FIG. 6)                                 Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          1.4231          0.0423                                             1          1.0641          0.0553                                             5          0.6795          0.0218                                             10         0.0000          0.0000                                             50         0.0032          0.0010                                             ______________________________________                                    

                  TABLE 11                                                        ______________________________________                                        Fraction of Cell Survival                                                     MCF7 With β-Lapachone (FIG. 7)                                           Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          1.0145          0.0783                                             1          0.9197          0.0687                                             5          0.0036          0.0020                                             10         0.0018          0.0010                                             50         0.0009          0.0005                                             ______________________________________                                    

                  TABLE 12                                                        ______________________________________                                        Fraction of Cell Survival                                                     MCF7 With "Drug A" (3,3-DINOR-Dunnione) (FIG. 7)                              Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          0.9854          0.0579                                             1          0.8540          0.0389                                             5          0.0036          0.0020                                             10         0.0018          0.0010                                             50         0.0018          0.0005                                             ______________________________________                                    

                  TABLE 13                                                        ______________________________________                                        Fraction of Cell Survival                                                     MCF7 With "Drug B" (3-NOR-Dunnione) (FIG. 8)                                  Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          0.8377          0.0593                                             1          0.0888          0.0444                                             5          0.0032          0.0020                                             10         0.0016          0.0010                                             50         0.0154          0.0035                                             ______________________________________                                    

                  TABLE 14                                                        ______________________________________                                        Fraction of Cell Survival                                                     MCF7 With "Drug C" (Dunnione) (FIG. 8)                                        Concentration of                                                              Drug (μM)                                                                             Fraction of Cell Survival                                                                     Standard Deviation                                 ______________________________________                                        0          1.1624          0.0781                                             1          0.5584          0.0674                                             5          0.0065          0.0041                                             10         0.0032          0.0013                                             50         0.0065          0.0013                                             ______________________________________                                    

Effectiveness against prostate cancer:

Additional biological testing was conducted to evaluate the efficacy ofthe tricyclic o-naphthoquinones against prostate cancer and to furtherevaluate the biological activity of the compounds against breast cancer.The compounds evaluated were as follows:

Drug B=3-NOR-Dunnione

Drug C=Dunnione

Drug D=3,3-DINOR-2,3-Dehydrodunnione

Table 15 lists the IC₅₀ determinations of Drugs B, C, and D against thehuman prostate cancer cell line PC-3 and the human breast cancer cellline MCF7.

                  TABLE 15                                                        ______________________________________                                        IC.sub.50 Determinations of Drugs B, C, and D on                              Human Prostate (PC-3) and Breast (MCF7) Cell Lines                            Structures           IC.sub.50 (μM)                                        Naphtho(2,3-b)dihydrofurandiones                                                                   PC-3   MCF7                                              ______________________________________                                        Drug B               0.7    0.5                                               Drug C               0.6    0.7                                               Drug D               0.9    0.7                                               ______________________________________                                    

IC₅₀ calculations for each cell line were determined by DNA amount andanchorage-dependent colony formation (CF) as described elsewhere. (SeePlanchon et al. Cancer Res. 55, 3706 (1995), incorporated herein byreference.) In short, IC₅₀ calculations for each cell line weredetermined by DNA amount and anchorage-dependent colony formation (CF)assays. For the CF assay, cells were seeded at 500 viable cells/well in6-well plates and incubated overnight, then treated with equal volumesof media containing β-lapachone at final concentrations ranging from0.005 to 50 μM in half-log increments (controls were treated with 0.25%DMSO, equivalent to the highest dose of β-lapachone used) for 4 hours orfor continuous 12 hour exposures. Plates (3 wells/condition) werestained with crystal violet, and colonies of >50 normal-appearing cellswere enumerated. IC₅₀ values for various cells were calculated usingdrug doses with numbers of colonies surrounding 50% of control. For DNAassays, plates were harvested for IC₅₀ determinations 8 days aftertreatment using a CytoFluor 2350 fluorescence measurement system(Millipore). Six-well samplings were included in the calculation of DNAfluor units for each dose. A graph of β-lapachone dose versus percentagecontrol DNA in fluor units was used to calculate each IC₅₀. The cellswere exposed for 24 hours to the tricyclic naphthoquinones. Allexperiments were repeated at least twice, each in duplicate. PC-3 is anandrogen-independent prostate cancer cell line.

To further study the presently described compounds, their ability toinduce apoptosis (programmed cell death) in human prostate and breastcancer cell lines was evaluated. The results are encouraging in the allof the compounds tested induced apoptosis at a concentration of 5 μM.

                  TABLE 16                                                        ______________________________________                                        Apoptopic Effects of B, C, and D on                                           Human Prostate (PC-3) and Breast (MCF7) Cancer Cell Lines                     Structures Apoptosis Observed                                                 Naphtho(2,3-b)                                                                           Concentrations                                                     dihydrofurandiones                                                                       1 μm                                                                              5 μm                                                                              10 μm                                                                            25 μm                                                                            50 μm                                                                            100 μm                          ______________________________________                                        Drug C     -      +      +     +     +     +                                  Drug B     +      +      +     +     +     +                                  Drug D     +      +      +     +     +     +                                  ______________________________________                                    

Quantification of apoptotic cells and alterations in cell cycledistribution were determined 24 hours after drug treatment (1.0-100 μm;4 h) by flow cytometry and DNA laddering as described by Planchon et al.supra. Experiments were repeated at least three times, each induplicate. The above results apply to both the PC-3 and MCF7 cell lines.

An illustrative method to determine apoptosis proceeds as follows: Cells(1×10⁶ /condition) were treated with or without various concentrationsof β-lapachone, topotecan, or camptothecin for various times.Trypsinized or pelleted cells were washed with ice-cold Tris/salinesolution (10 mM Tris (pH 7.0) and 50 mM NaCl), fixed in 90%ethanol-Tris/saline, and stored at -4° C. Cells were washed withphosphate-citric acid buffer (0.2M Na₂ HPO₄ and 0.1M citric acid (pH7.8)) and stained with a solution containing 0.2% NP40, RNase A (7000units/ml), and 33 μg/ml propidium iodide at 4° C. for 10 minutes.Stained nuclei were then analyzed for DNA-propidium fluorescence using aBecton Dickinson FACScan (San Jose, Calif.) at a laser setting of 36 mWand an excitation wavelength of 488 nm. Resulting DNA distributions werethen analyzed for proportion cells in apoptosis, G₀ /G₁, S, and G₂ /M ofthe cell cycle. Data was analyzed by ModFit (Verity Software House,Inc., Topsham, ME). All experiments were repeated at least three times,each in duplicate.

Cells from the above conditions were also analyzed for the formation of180-200bp DNA laddering, which can be diagnostic for certain cellsundergoing apoptosis. Treated and control cells were washed twice withPBS containing 1 mM EDTA at ambient temperature and lysed in 10 mM EDTA,to mM Tris-HC1 (pH 8.0), 0.5% (w.v) sodium lauryl sarkosinate, and 0.5mg/ml RNase A for at least 1 hour at 37° C. and then with 1.0 mg/mlproteinase K at 37° C. for at least 1 hour. Loading buffer (10 mM EDTA,1% (w/v) low melting point agarose, 0.25% (w.v) bromophenol blue, and40% (w.v) sucrose) was then added (10% final concentration), and heated(70° C.) samples were loaded onto presolidified, 1.8% (w/v) agarose gelscontaining 0.1 /μg/ml ethidium bromide using end-cut Rainin (Woburn,Mass.) 1-ml pipette tips to avoid DNA shearing. Agarose gels were run at65 V/cm for 10 minutes and then at 15 V/cm overnight in 1×TAE (1.0MTris-acetate (pH 7.5) and 10 mM EDTA) running buffer.

Inhibition of Topoisomerase I and II:

Once it had been discovered that the tricyclic compounds describedherein would not only inhibit cell growth, but would actively inducecell death via apoptosis, a mechanism to account for these biologicaleffects was investigated. As shown in Table 17, it was found that thecompounds of the present invention are inhibitors of Topoisomerase I(Topo I). By inhibiting the function of Topo I, which catalyzes theunwinding of DNA strands prior to replication, it is hypothesized thatthe compounds described above induce cell death by preventing access tothe genetic information necessary to carry on normal cellularoperations.

                  TABLE 17                                                        ______________________________________                                        Inhibition of the Catalytic Activity of                                       Topoisomerase I by Drugs B, C, and D                                          Structures    Inhibition of Topoisomerase I                                   Naphto (2,3-b) furan diones                                                                 1 μm 10 μm 100 μm                                                                            1 mM                                    ______________________________________                                        Drug C        -       +        +      +                                       Drug B        +       +        +      +                                       Drug D        -       -        +      +                                       ______________________________________                                    

Topoisomerase I (Topo I) from human placenta (3.0 units) was incubatedwith various concentrations of Drug B, C, or D for 10 min. at 37° C.p36B4 Supercoiled plasmid DNA (1.5 μg) was then added to initiate DNAunwinding reactions. Topo I DNA unwinding activity was measured asdescribed in Hsiang et al. J. Biol. Chem., 260, 14873 (1985),incorporated herein by reference.

Topoisomerase I enzymatic activity can be assayed in the followingmanner: supercoiled DNA unwinding assays using purified human placentaTopo I (TopoGEN, Inc., Columbus, Ohio) were performed with or withoutdrug addition to assess the inhibitory effects of β-lapachone,camptothecin, and topotecan under various reaction conditions. Enzymaticassays were performed in two basic fashions. In the first reactionsequence, Topo I (3.0 units) was incubated with increasingconcentrations of β-lapachone, camptothecin (or topotecan), or DMSO for5 minutes at 37° C. in Topo I reaction buffer (without dATP). p36B4Supercoiled DNA (1.5 μg) was then added to begin the reactions, andaliquots were taken at various times. In the second reaction sequence,p364B4 DNA (1.5 μg) was incubated with various β-lapachone,camptothecin, or topotecan concentrations for 5 minutes at 36° C., andTopo I (3.0 units) was added at t=0. Aliquots were removed at varioustimes to follow DNA unwinding reactions and immediately treated withSDS-proteinase K at 65° C. and loaded onto 0.7% agarose gels;supercoiled (form 1) substrate was separated and quantified fromreaction intermediates (R) and open circular (form II) product. On mostagarose gels, DNA molecular weight markers (λDNA cut from EcoRl-Hindlll(marked "Lambda EcoRI DNA Marker"); Sigma Chemical Co., St. Louis, Mo.),linearized p36B4 plasmid DNA (cut with PstI), and p36B4 plasmid DNAsubstrate were concomitantly added. Gels were stained with 50 μg/mlethidium bromide and destained for 30 minutes in distilled water; theloss of form I relative to total DNA loaded was quantified bydensitometric scans of photographic negatives (type 55; Polaroid,Cambridge, Mass.). Enzyme inhibition was defined as the effects ofvarious drugs on Topo I activity compared to control (DMSO alone)reactions.

Analogous experiments to assay the ability of several of the compoundsdescribed herein to induce Topoisomerase II (Topo II)-mediated DNAcleavage were also performed. The results of one such experiment aredepicted in the electrophoretegram of FIGS. 9A and 9B. Here, DNA wasincubated in the presence of Topo II and several different compoundsdescribed herein. The electrophoresis plate run depicted in FIGS. 9A and9B shows that the naphthoquinone derivatives described herein have theability to form Topo II-drug DNA-cleaving complexes.

As detailed herein, the β-lapachone and dunnione analogs of the presentinvention have been shown to exhibit a broad spectrum of anti-canceractivity. The analogs are equally potent against humanmultidrug-resistant cancer cells. The gel depicted in FIGS. 9A and 9Bshow that DNA Topo II is an intracellular target of the compoundsdescribed herein. The compounds stimulate Topo II-mediated DNA cleavage.The compounds also induce Topo II-mediated cleavage using purifiedmammalian Topo II. However, unlike other Topo II drugs, the DNA cleavagepatterns induced by the naphthoquinone compounds were similar tobackground Topo Il-induced cleavage.

The compounds described herein also inhibited Topo II catalytic activityin a P4 knotting assay (data not shown). The inhibition appears to be aspecific interaction of the compounds with the Topo II-mediatedreaction: the compounds induce very slight unwinding in a plasmid DNAunwinding assay. Furthermore, the compounds tested induced DNA cleavageand protein-DNA cross-links in cultured mammalian cells. This suggeststhat the anti-tumor activity of the compounds is due to a specificinteraction with Topo II.

A legend for the compounds which were tested in FIGS. 9A and 9B is asfollows: ##STR25## Lane 1: R=H (β-lapachone) Lane 2: R=OH

Lane 3: R=OC(O)CH₃

Lane 4: R=CH₂ CH=CH₂

Lane 5: R=OC(O)CH₂ CH₂ NH₃ ⁺ Br

Lane 6: R=OC(O)CH₂ CO₂ H

Lane 7: 4-pentyloxy-1,2-naphthoquinone ##STR26## Lane 8: "Drug B,"3-NOR-dunnione Lane 9: dunnione

Lane 7 contains a 4-alkoxy-1,2-naphthoquinone, namely4-pentyloxy-1,2-naphthoquinone. 4-(C₁ -C₆ alkoxy)-1,2-naphthoquinones,as well as several other types of 4-substituted-1,2-naphthoquinones,including 4-(C₁ -C₆ alkenyloxy)-1,2-naphthoquinones, 4-(C₁ -C₆carbonyloxy)-1,2-naphthoquinones, 4-(C₁ -C₆aryloxy)-1,2-naphthoquinones, 4-(C₁ -C₆heteroaryloxy)-1,2-naphthoquinones, 4-(benzyloxy)-1,2-naphthoquinone,4-(C_(3-C) ₆ cycloaryloxy)-1,2-naphthoquinones, and 4-(C_(3-C) ₆heterocycloaryloxy)-1,2-naphthoquinones can be synthesized by reacting asilver salt of lawsone with a haloalkane in a suitable solvent (e.g.,benzene). The resulting solution is then washed with ethyl acetate todissolve the organic products and then filtered to remove the silversalts. The ethyl acetate solution is washed with NH₄ OH, followed byNaHSO₃. The NaHSO₃ extracts are combined, treated with Na₂ CO₃ andextracted with CH₂ Cl₂. The CH₂ Cl₂ extracts are combined and dried.Removal of the solvent, as by evaporation, yields the 4-alkoxy-1,2-naphthoquinone product. If desired, the product can be furtherpurified by re-crystallization from benzene-ligroin.

The gels shown in FIGS. 9A and 9B show that Topo II is an intracellulartarget of β-lapachone, dunnione, and their derivatives. In the farleft-hand lane of FIG. 8A, DNA alone is shown. Moving to the right, thenext lane contains DNA and Topo II (mammalian). Lanes 1-9 of FIGS. 9Aand 9B contain a series of concentrations of drugs (see Legend, above)in the presence of DNA and Topo II. Each set of lanes for each drugspans 3 orders of magnitude in concentration (0.1, 1, 10, and 100 μM).In FIG. 9A, the second lane from the left, which contains DNA and TopoII, shows very little DNA cleavage. The far left-hand lane of FIG. 9A,which contains DNA alone, shows no cleavage products. However, Lanes1-9, which contain DNA, Topo II, and a drug according to the presentinvention, show extensive DNA cleavage. The wide range ofdifferently-sized cleavage products indicates that the cleavage isextensive and heterogeneous.

Pharmaceutical Dosage Forms

The above-described compounds being effective to inhibit the growth ofcancer cells, the compounds are suitable for the therapeutic treatmentof neoplastic conditions in mammals, including humans. Cancer cellgrowth inhibition at pharmacologically-acceptable concentrations hasbeen shown in human breast cancer, colon cancer, lung cancer, andprostate cancer cell lines, as described above.

The compounds described herein are administratable in the form oftablets, pills, powder mixtures, capsules, injectables, solutions,suppositories, emulsions, dispersions, food premixes, and in othersuitable forms. The pharmaceutical dosage form which contains thecompounds described herein is conveniently admixed with a non-toxicpharmaceutical organic carrier or a non-toxic pharmaceutical inorganiccarrier. Typical pharmaceutically-acceptable carriers include, forexample, mannitol, urea, dextrans, lactose, potato and maize starches,magnesium stearate, talc, vegetable oils, polyalkylene glycols, ethylcellulose, poly(vinylpyrrolidone), calcium carbonate, ethyl oleate,isopropyl myristate, benzyl benzoate, sodium carbonate, gelatin,potassium carbonate, silicic acid, and other conventionally employedacceptable carriers. The pharmaceutical dosage form may also containnon-toxic auxiliary substances such as emulsifying, preserving, orwetting agents, and the like.

EXAMPLES

The following Examples are provided solely to aid in a clearunderstanding of the presently claimed invention. The following Examplesdo not limit the scope of the invention described above or claimedherein in any fashion.

Preparation of C-allyl and O-allyl ether derivatives of lawsone

With reference to Reaction I, above, lawsone(2-hydroxy-1,4-naphthoquinone) (52.25 g, 300 mmol) was dissolved inanhydrous DMSO (350 mL) at 23° C. The solution was cooled to -78° C.,and lithium hydride (2.50 g, 315 mmol) was added to the solid. The solidsolution was then allowed to warm up slowly to 23° C. When gas evolutionsubsided, lithium iodide (10.0 g, 75 mmol) was added, followed by theallyl bromide (34.6 mL, 300 mmol), which was added dropwise. The mixturewas stirred for 5 hours at 45° C. and then for 10 hours at 23° C. Afterquenching the reaction with ice (200 g), water was added to the reaction(700 mL), followed by concentrated HCl (70 mL) and ethyl acetate (500mL). Undissolved solids were collected by filtration and were confirmedto be the allyloxy-1,4-naphthoquinone (14, 20 g, 30%).

Dimethylallyloxy-1,4-naphthoquinone (14, R=R'=Me): ¹ H NMR (CDCl₃. 300MHz): δ 8.20-8.00 (m, 2H), 7.86-7.58 (m, 2H), 6.16 (s, 1H), 4.49 (t,J=6.8 Hz. 1H), 4.59 (d, J=6.8 Hz, 2H), 1.81 (s, 3H), 1.76 (s, 3H).

2-Methylallyloxy-1,4-naphthoquinone (14, R=H, R'=Me): mp 136.0-137.0°C., ¹ H NMR (CDCl₃, 300 MHz) δ 8.13 (dd, J=7, 2 Hz, 1H), 8.08 (dd, J=7,2 Hz, 1H), 7.75 (dt, J=7, 2 Hz, 1H), 7.70 (dd, J=7, 2 Hz, 1H), 6.17 (s,1H), 6.00-5.90 (m, 1H), 5.8-5.7 (M, 1H), 4.53 (d, J=6 Hz, 2H), 1.78 (d,J=6 Hz, 3H).

2-Allyloxy-1,4-naphthoquinone (14, R=R'=H): ¹ H NMR (CDCl₃, 300 MHz) δ8.22-8.04 (m, 2H), 7.94-7.66 (m, 2H), 6.17 (s, 1H), 6.15-5.95 (m, 1H),5.49(dd, J=11.6, 1.2 Hz, 1H), 5.41 (dd, J=10.5, 1.2 Hz, 1H), 4.62 (d,J=5.6 Hz, 2H).

The ethyl acetate layer was then separated and aqueous layer extractedagain with more ethyl acetate (250 mL). The combined organic layers werethen extracted with 5% aqueous NaHCO₃. The NaHCO₃ extracts wereacidified with concentrated HCl and the precipitate filtered. Theprecipitate was shown to be unreacted lawsone (10) (16.02 g, 30%).

The ethyl acetate solution was evaporated in vacuo and the residuedissolved in diethyl ether (500 mL). The ether solution was extractedwith 2N NaOH (3×200 mL). The alkaline extracts were acidified withconcentrated HCl and allowed to stand at 4° C. for 15 hours. Theprecipitate was filtered, dried, and re-crystallized from a mixture ofEtOH/H₂ O to afford (13) as yellow crystals.

3-(Dimethylallyl)-2-hydroxy-1,4-naphthoquinone (13, R=R'=Me) (28.76 g,40%): ¹ H NMR (CDCl₃, 300 MHz) δ 8.12 (d, J=7.5 Hz, 1H), 8.07 (d, J=7.5,1H), 7.75 (t, J=7.5 Hz, 1H), 7.67 (t, J=7.5 Hz, 1H), 7.29 (s, OH), 5.21(t, J=7.3 Hz, 1H), 3.31 (d, J=7.3 Hz, 1H), 1.79 (s, 3H), 1.68 (s, 3H).

3-(Methylallyl)-2-hydroxy-1,4-naphthoquinone (13, R=H, R'=Me) (36%): mp130.5-131.5° C.; ¹ H NMR (CDCl₃, 300 MHz) δ 8.13 (dd, J=7.5, 1.3 Hz,1H), 8.08 (dd, J=7.5, 1.3 Hz, 1H), 7.76 (td, J=7.5, 1.3 Hz, 1H), 7.68(td, J=7.5, 1.3 Hz, 1H), 7.36 (s, OH), 5.40-5.70 (m, 2H), 3.29 (d, J=6.0Hz, 2H), 1.62 (d, J=6.0 Hz, 2H).

3-Allyl-2-hydroxy-1,4-naphthoquinone (13, R=R'=H) (39%): ¹ H NMR (CDCl₃,300 MHz) δ 8.13 (dd, J=7.7, 1.1 Hz, 1H), 8.09 (dd, J=7.6, 1.1 Hz, 1H),7.76 (dt, J=7.5, 1.5 Hz, 1H), 7.69 (dt, J=7.5, 1.4 Hz, 1H), 7.33 (s,OH), 6.08-5.80 (M, 1H), 5.17 (dd, J=17.1, 1.6 Hz, 1H), 5.05 (dd, J=10.0,1.5 Hz, 1H), 3.37 (dt, J=6.5, 1.4 Hz, 2H).

The Claisen rearrangement

Referring now to Reaction III, above, a solution of (14) (20 g) intoluene (250 mL) was heated to reflux. The solids dissolved gradually asthe temperature increased and a clear red-pink solution resulted. Afterheating under reflux for 1.5 h, the solution was allowed to cool and 2NNaOH (100 mL) was added. The solution was filtered to separate unreactedally ether (14) (2.24 g, 11%). The aqueous layer was separated and thetoluene layer was extracted with more 2N NaOH (2×50 mL). The combinedaqueous layers were acidified with concentrated HCl and extracted withethyl acetate. The organic extracts were dried, concentrated in vacuo,and the residue re-crystallized from EtOH/H₂ O to afford (17).

3-(Dimethylallyl)-2-hydroxy-1,4-naphthoquinone (17, R=R'=Me) (12.67 g,63%): ¹ H NMR (CDCl₃, 300 MHz) δ 8.10-8.00 (m, 2H), 7.84 (s, OH),7.80-7.60 (m, 2H), 6.29 (dd, J=17.5, 10.6 Hz, 1H), 5.04-4.93 (m, 2H),1.57 (s, 6H).

3-(Methylallyl)-2-hydroxy-1,4-naphthoquinone (17, R=H, R'=Me) (30%): ¹ HNMR (CDCl₃, 300 MHz) δ 8.12 (dd, J=7.7, 1.1 Hz, 1H), 8.07 (dd, J=7.6,1.2 Hz, 1H), 7.76 (dt, J=7.5, 0.9 Hz, 1H), 7.68 (dt, J=7.5, 1.3 Hz, 1H),6.20 (ddd, J=17.3, 10.1. 7.4 Hz, 1H), 5.14 (dd, J=17.1, 1.5 Hz, 1H),5.02 (dd, J=10.1, 1.3 Hz, 1H), 3.99 (m, 1H), 1.41 (d, J=7.1 Hz, 3H).

Preparation of β-lapachone and analogs

Cyclization via treatment with strong acid

One technique to form the third ring of the tricyclic compounds is totreat the allyl intermediate with concentrated acid. With reference toReactions II and III, concentrated sulfuric acid (70 mL) was added tolapachol (13) (11.26 g) (or 17 in Reaction III) at 23° C. After stirringuntil all solids dissolved (approximately 15 minutes), the mixture waspoured into water (200 mL) and filtered to afford β-lapachone (15,R5=R6=Me) (11.11 g, 99%).

Re-crystallization from diethyl ether gave β-lapachone as orange needles(10.45 g, 94% recovery): mp 154-155.5° C., ¹ H NMR (CDCl₃, 300 MHz) δ8.06 (d, J=7.7 Hz, 1H), 7.81 (d, J=7.7 Hz, 1H), 7.64 (t, J=7.7 Hz, 1H),7.50 (t, J=7.5 Hz 1H), 2.58 (t, J=6.7 Hz, 2H), 1.86 (t, J=6.7 Hz, 2H),1.47 (s, 6H).

Monomethyl-β-lapachone (15, R=H, R'=Me) (48% along with 22% α-isomerafter silica gel chromatography): mp 164-165° C.; ¹ H NMR (CDCl₃, 300MHz) δ 8.07 (dd, J=7.6, 1.5 Hz. 1H), 7.82 (dd, J=7.6, 1.2 Hz, 1H), 7.65(dd, J=7.6, 1.5 Hz, 1H), 7.51 (dd, J=7.6, 1.2 Hz, 1H), 4.40 (dqd, J=10,6.3, 3 Hz, 1H), 2,71 (ddd, J=17.5, 5.5, 3.5 Hz, 1H), 2.46 (ddd, J=17.5,10.7, 6.0 Hz, 1H), 2.11 (dddd, J=14, 6, 3.5, 3, 1H), 1.71 (dddd, J=14,10.7, 10, 5.5 Hz, 1H), 1.54 (d, J=6.3 HZ, 3H).

Dunnione (16, R=R'=Me): ¹ H NMR (CDCl₃, 300 MHz) δ 8.04 (d, J=7.5 Hz,1H), 7.68-7.50 (m, 3H), 4.67 (q, J=6.7 Hz, 1H), 1.47 (d, J=6.7 Hz, 3H),1.45 (s, 3H), 1.27 (s, 3H).

3-NOR-dunnione (16, R=H, R'=Me, R2 and R4=H) (30%): ¹ H NMR (CDCl₃, 300MHz) δ 8.08 (d, J=7.4 Hz, 1H), 7.72-7.50 (m, 3H), 5.24-5.12 (m, 1H),3.60-3.48 (m, 1H), 1.54 (d, J=6.7 Hz, 3H), 1.24 (d, J=7.1 Hz, 3H).

Cyclization via epoxidation to yield 3-substituted lapachones:

Referring now to Reaction IV, 3-hydroxy-β-lapachone (19) and derivativesthereof can be synthesized by forming an epoxide intermediate followedby ring closure. An illustrative synthesis of 3-hydroxy-β-lapachone (19,R5=R6=Me, R7=OH) proceeds as follows:

Lapachol (12.11 g, 50 mmol) was dissolved in CH₂ Cl₂ (250 mL) at 23° C.The solution was cooled to 0° C., which caused some lapachol toprecipitate. To this cooled solution was added m-chloroperoxybenzoicacid (m-CPBA) (10.15 g, 85% purity, 50 mmol). The solution then wasstirred for 4 hours at 23° C., and the solution filtered. The filtratewas washed with aqueous NaHCO₃ and dried.

The epoxide so formed (18) remains in solution. To this solution wasadded BF₃.OEt₂ (6.15 mL, 50 mmol) at 0° C. After stirring at 23° C. for10 hours, the solution was washed consecutively with aqueous Na₂ CO₃, 5%citric acid, and water. The organic layer was extracted with 5% NaHSO₃(300 mL, 200 mL, 200 mL). The extracts were pooled. Saturated Na₂ CO₃(600 mL) was added to the pooled extracts to yield reddish precipitates.The solution containing the precipitates was cooled at 0° C. for 2 hoursand filtered.

The filtrate is 3-hydroxy-β-lapachone (19, R=R'=Me, R"=H) (6.72 g, 52%for the two steps from lapachol): mp 202.5-203.5° C., ¹ H NMR (CDCl₃,300 MHz) δ 8.06 (d, J=7.6 Hz, 1H), 7.84 (d, J=7.6 Hz, 1H), 7.66 (t,J=7.6 Hz, 1H), 7.52 (t, J =7.6 Hz, 1H), 3.92 (m, 1H), 2.83 (dd, J=17.7,4.8 Hz, 1H), 2.62 (dd, J=17.7, 5.4 Hz, 1H), 1.52 (s, 3H), 1.46 (s, 3H).

2-Hydroxy-3-(2',3'-oxo-3'methylbutyl)naphthoquinone (18). This compoundcan be obtained by repeating the reaction described immediately above,and isolating the epoxide by silica gel chromatography (25-100% ethylacetate in hexanes). ¹ H NMR (DMSO-d6, 300 MHz) δ 8.04-7.95 (m, 2H),7.87-7.72 (m, 2H), 3.52 (t, J=6.5 Hz, 1H), 2.65 (d, J=6.8 Hz, 2H), 1.10(s, 6H); ¹³ C NMR (CDCl₃, 75 MHz) δ180.92 (s), 175.13 (s), 169.94 (s),134.53 (d)<131.88 (d), 130.43 (s), 129.23 (d), 127.21 (s), 124.50 (d),115.94 (s), 93.59 (d), 71.52 (s), 27.26 (t), 25.62 (q), 24.56 (q).

Fully-Aromatic Dunnione Analogs

With reference to Reaction V, above, the fully-aromatic derivative ofdunnione, namely 2-methyl-4H,5H-naphtho(2,3-b)furan-6,7-dione (21), canbe synthesized by reacting lawsone with an aldehyde.

Illustratively, 2-hydroxy-3-propenyl-1,4-naphthoquinone (20) wassynthesized, followed by ring closure to yield the fully-aromaticdunnione derivative, as follows:

Propionaldehyde (RCHO, R=propyl, 5.0 mL, 69.3 mmol) was added to asolution of concentrated HCl (2 mL) and lawsone (2.00 g, 11.5 mmol) inacetic acid (35 mL) at 60° C. After stirring for 1.25 hours, anotherportion of propionaldehyde was added (5.0 mL, 69.3 mmol). The solutionwas then stirred for an additional 1 hour. The solution was allowed tocool to room temperature, and then ice water (200 mL) was added toquench the reaction. The solution was extracted with diethyl ether(3×200 mL) and the organic fractions pooled. The combined organic layerswere re-extracted with 5% Na₂ CO₃ (8×150 mL). The aqueous extracts werealso pooled and acidified with concentrated HCl. A precipitate formedwhich was collected by filtration to afford (20) as an orange solid.2-Hydroxy-3-propenyl-1,4-naphthoquinone (20) (983 mg, 40%): mp 133-134°C.; ¹ H NMR (CDCl₃, 300 MHZ) δ 8.13 (d, J=7.7 Hz, 1H), 8.06 (d, J =7.5Hz, 1H), 7.80-7.62 (m, 3H), 7.15-6.95 (m, 1H), 6.63 (d, J=16.1 Hz, 1H),1.99 (d, J=6.8 Hz, 3H).

Ring closure to yield 2-methyl-4H, 5H-naphtho 2,3-b!furan-6,7-dione (21)can be accomplished as follows. A solution of the naphthoquinone (20)(2.26 g) and Hg(OAc)₂ (5.0 g) in acetic acid (200mL) was stirred for 10hours at 23° C. The precipitate formed which was removed by filtration.The filtrate was poured into water (400 mL), and the resultant solutionwas extracted with ethyl acetate (3×200 mL). The combined extracts werewashed with water (3×200 mL). After drying over MgSO₄, the organic layerwas concentrated in vacuo, and the residue was purified bychromatography (10-20% ethyl acetate in hexane) on silica gel to give(21) as a brown-red solid.

2-Methyl-4H, 5H-naphtho(2,3-b)furan-6,7-dione (21,(3,3-DINOR-2,3-dehydrodunnione)): (549 mg, 25%) mp 158.5-160°; ¹ H NMR(CDCl₃, 300 MHz) δ 8.05 (d, J=7.6 Hz, 1H), 7.68-7.57 (m, 2H), 7.43 (dt,J=7.3, 1.8 Hz, 1H), 6.45 (s, 1H) 2.43 (s, 3H); ¹³ C NMR (CDCl₃, 75 MHz)δ 180.73 (s), 174.40 (s), 159.64 (s), 155.97 (s), 135.39 (d), 130.47(d), 129.82 (d), 128.72 (s), 128.60 (s), 122.70 (s), 121.99 (d), 104.55(d), 13.63 (q); MS m/z 69, 128, 183, 212; HRMS m/z calculated for C₁₃ H₈O₃ (M+) 212.0473, found 212.0471.

Derivatization of 3-hydroxy-β-lapachone

Once 3-hydroxy-β-lapachone has been isolated, its hydroxyl functionalitycan be utilized to synthesize a wide range of 3-oxy-substitutedβ-lapachone derivatives. What follows are examples of a mono-acidderivative, an amino acid derivative, and a di-acid derivative. Basedupon these illustrative syntheses, several analogous derivatives can besynthesized with ease.

With reference to Reaction VI, above, 1,1'-carbonyldiimidazole (486 mg,3.0 mmol) was first added to the corresponding carboxylic acid (3.0mmol) in dimethylformamide (DMF) (8 mL) at 23° C. For the followingexamples only, R¹⁰ of the acid and corresponding 3-substituted lapachoneproduct can be CH₂ CH₂ NHBoc- (Boc=t-butoxycarbonyl) (22a), CH₂ CO₂C(CH₃)₂ - (22b), or methyl (22c).

After stirring for 20 minutes, 3-hydroxy-β-lapachone (19) (517 mg, 2.0mmol) and DBU (389 uL, 26 mmol) were added to the mixture.(DBU=1,8-diazabicyclo (5.4.0)undec-7-ene, a relatively strong,sterically-hindered, non-nucleophilic base.) The mixture was stirred for5 hours and poured into water (150 mL). The precipitate was collected byfiltration and purified by silica gel chromatography (10-33% ethylacetate in hexanes) to afford (22) (approximately 50% yield).

With reference to Reaction VII, compound (22a) (200 mg, 0.466 mmol) wasadded to diethyl ether (200 mL). A small amount of undissolved residuewas removed by filtration. To the clear solution, hydrogen bromide (35%in acetic acid, 3.0 mL) was added at 23° C. After stirring for 10minutes, the solution was filtered, and the precipitate re-crystallizedfrom methanol to afford (23) (52 mg, 27%): ¹ H NMR (D₂ O, 300 MHz) δ8.05-7.60 (m, 4H), 5.13 (m, 1H), 3.10 (t, J=6.5 Hz, 2H), 2.84-2.50(M,4H), 1.39 (s, 3H), 1.31 (s, 3H).

Referring now to Reaction VIII, trifluoroacetic acid (1.0 mL) was addedto a solution of compound (22b) (330 mg) in CH₂ Cl₂ (1.5 mL) at 23° C.After stirring 1 hour the mixture was concentrated in vacuo. The residuewas dissolved in MeO-t-Bu (50 mL) and extracted with saturated NaHCO₃(2×25 mL). The combined aqueous layers were counter-extracted withdiethyl ether and acidified with concentrated HCl. The resultantprecipitate was filtered to give the malonyl derivative (24) (136 mg,48%): ¹ H NMR (CDCl₃, 300 MHz) δ 8.08 (d, J=7.6 Hz, 1H), 7.85 (d, J=7.8Hz, 1H), 7.69 (t, J=7.6 Hz, 1H), 7.55 (t, J=7.5 Hz, 1H), 5.19 (t, J=4.6Hz, 1H), 3.36 (s, 2H), 2.84 (dd, J=18.2, 4.9 Hz, 1H), 2.73 (dd, J=18.2,4.4 Hz, 1H), 1.52 (s, 3H), 1.48 (s, 3H); ¹³ C NMR (CDCl₃, 75 MHz) δ179.43 (s), 178.64 (s), 170.12 (s), 161.22 (s), 134.98 (d), 132.07 (s),131.08 (d), 130.21 (s), 128.93 (d), 124.37 (d), 110.12 (s), 79.76 (s),69.11 (d), 24.98 (q), 23.29 (q), 22.71 (t), 21.02 (q); MS (FAB) m/z 136,154, 241, 345 (MH⁺).

3-(n-Butyloxycarboxy-β-alanyloxy)-β-lapachone (22a): ¹ H NMR (CDCl₃, 300MHz) δ 8.10 (d, 1H), 7.84 (d, 1H), 7.67 (t, 1H), 7.54 (t, 1H), 5.17 (t,1H), 3.53-3.32 (m, 1H), 2.93 (br, 1H), 2.85 (dd, 1H), 2.70 (dd, 1H),2.65-2.50 (m, 1H), 1.47 (d, 6H), 1.42 (s, 9H).

3-(β-Alanyloxy)-β-lapachone (23): mp 228-229° C. (decomposed); ¹ H NMR(D₂ O, 300 MHz) δ 8.05-7.60 (m, 4H), 5.13 (m, 1H), 3.10 (t, J=6.5 Hz,2H), 2.84-2.50 (m, 4H), 1.39 (s, 3H); ¹³ C NMR (D₂ O, 75 MHz, DMSO-d6was added as internal standard) δ 181.77 (s), 180.84 (s), 173.02 (s),165.13 (s), 137.45 (d), 132.93 (s), 130.79 (s), 130.03 (d), 126.34 (d),110.92 (s), 82.29 (s), 71.99 (d), 36.34 (t), 32.57 (t), 25.41 (q), 24.10(q), 23.35 (t); MS (FAB) m/z 122.0, 205.1, 241.1, 301.1, 330.1, (MH⁺),659.1 (2M+H⁺).

3-(2'-t-Butyloxycarboxyacetoxy)-β-lapachone (22b) (27%): ¹ H NMR (CDCl₃,300 MHz) δ 8.10 (d, 1H), 7.84 (d, 1H), 7.68 (t, 1H), 7.55 (t, 1H), 5.22(t, 1H), 3.33 (s, 2H), 2.95 (dd, 1H), 2.74 (dd, 1H), 1.52 (d, 6H), 1.42(s, 9H).

3-Acetoxy-β-lapachone (22c): ¹ H NMR (CDCl₃. 300 MHz) δ 8.09 (d, J=7.6Hz, 1H), 7.85 (d, J=7.8 Hz, 1H), 7.68 (t, J=7.6 Hz, 1H), 7.55 (t, J=7.6Hz, 1H), 5.15 (t, J=4.5 Hz, 1H), 2.82 (dd, J=18.2, 4.8 Hz, 1H), 2.68(dd, J=18.2, 4.1 Hz, 1H), 2.08 (s, 3H), 1.49 (s, 3H), 1.44 (s, 3H); ¹³CNMR (CDCl₃, 75 MHz) δ 179.43 (s), 178.64 (s), 170.12 (s), 161.22 (s),134.98 (d), 132.07 (s), 131.08 (d), 130.21 (s), 128.93 (d), 124.37 (d),110.12 (s), 79.76 (s), 69.11 (d), 24.98 (q), 23.29 (q), 22.71 (t), 21.02(q).

It is understood that the invention is not confined to the particularchemical reactions, reagents, solvents, transformations, or cell linesherein illustrated and described, but embraces all such modified formsthereof as come within the scope of the following claims.

What is claimed is:
 1. A compound of Formula II: ##STR27## wherein R⁵and R⁶ are each, independently, selected from the group consisting of H,C₁ -C₆ alkyl, C₁ -C₆ alkenyl, C₁ -C₆ alkoxy, C₁ -C₆ alkoxycarbonyl,--(CH₂)_(n) -aryl, and --(CH₂)_(n) -phenyl; and R⁷ is selected from thegroup consisting of --(CH₂)_(n) -amino, β-alanyl, malonyl, --(CH₂)_(n)-aryl, and --(CH₂)_(n) -phenyl, and n is an integer of from 0 to 10, andsalts thereof.
 2. The compound according to claim 1, wherein thecompound is selected from the group consisting of3-(β-alanyl)-β-lapachone and 3-malonyl-β-lapachone.
 3. A pharmaceuticalunit dosage form comprising an amount of a compound of Formula II:##STR28## wherein R⁵ and R⁶ are each, independently, selected from thegroup consisting of H, C₁ -C₆ alkyl, C₁ -C₆ alkenyl, C₁ -C₆ alkoxy, C₁-C₆ alkoxycarbonyl, --(CH₂)_(n) -aryl, and --(CH₂)_(n) -phenyl; and R⁷is selected from the group consisting of --(CH₂)_(n) -amino, β-alanyl,malonyl, --(CH₂)_(n) -aryl, and --(CH₂)_(n) -phenyl, and wherein n is aninteger of from 0 to 10; pharmaceutically-suitable salts thereof, andcombinations thereof; andwherein the amount is effective to inhibitgrowth of cancer cells in a human cancer patient followingadministration thereto.
 4. The pharmaceutical unit dosage form of claim3, comprising an amount of a compound selected from the group consistingof3-(β-alanyl)-β-lapachone and 3-malonyl-β-lapachone,pharmaceutically-acceptable salts thereof, and combinations thereof. 5.The pharmaceutical unit dosage form of claim 4 in combination with apharmaceutically-acceptable carrier.
 6. The pharmaceutical unit dosageform of claim 5, wherein the carrier is a solid carrier.
 7. Thepharmaceutical unit dosage form of claim 5, wherein the carrier is aliquid carrier.